CompletedNot Applicable

Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks

United States180 participantsStarted 2016-04-04

Plain-language summary

This study attempts to identify two types of AD by using clinical and cognitive tasks and brain imaging. The subtypes of AD are separated into a "typical" group (memory loss) and a "variant" group (language, visuospatial, and other cognitive difficulties). Performance on the clinical tasks and brain imaging will be compared among the young-onset Alzheimer's disease group, a late-onset Alzheimer's disease group, and a control group.

Who can participate

Age range50 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Meet criteria for AD.
✓. Meet clinical criteria for either typical amnestic AD or variant phenotypes of early-onset (EOAD, or "Type 2 AD").
✓. Mild-moderate dementia severity
✓. Sufficient English fluency to complete neuropsychological testing in English.
✓. Ability to provide consent for participation, or willingness to provide assent and a legally-authorized representative willing to provide surrogate consent.
✓. Availability of a caregiver informant for participation

Exclusion criteria

✕. Complicating medical illnesses.
✕. Significant primary visual impairments.
✕. Major psychiatric illness not due to the dementia.
✕. Confounding medications.
✕. Score 28/30 or higher on the Folstein Mini-Mental Status Exam.
✕. Age 40-85 years old
✕. Able to provide consent for participation and express willingness to participate in one-year follow-up visits.
✕. Have sufficient English fluency to complete neuropsychological testing in English.

What they're measuring

Alzheimer's disease Subtype

Timeframe: Performed at baseline

Trial details

NCT IDNCT03153371

SponsorUniversity of California, Los Angeles

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-08-31

View on ClinicalTrials.gov More Alzheimer Disease, Early Onset trials